Pens for the diabetes drug Ozempic sit on a production line at the Danish drugmaker Novo Nordisk’s site in Hillerod, Denmark in 2023.Tom Little/Reuters
Listen to this episode by clicking above or subscribe to The Decibel on your favourite podcast app or platform: Apple Podcasts, Spotify, Amazon Music, iHeartRadio, Pocket Casts and YouTube.
The first episode of Skinny Inc. was all about the science behind GLP-1s, and the second episode was about the business, from the pharmaceutical companies who make GLP-1s to the insurance plans that may or may not cover it.
Today, we’re exploring how the so-called “Ozempic era,” affects people’s mental health.
First, business owner Maiyhet Burton tells us how using a GLP-1 has helped her body image. Globe health reporter Kelly Grant details how experts are split on the effect of GLP-1s on weight stigma, and psychotherapist Zoë Bisbing explains how the body positive movement helps her clients.
Plus, Tigress Osborn, executive director of the National Association to Advance Fat Acceptance on why the popularity of GLP-1s shows how far we have to go with anti-fat discrimination, and Ary Mahraj and Emily Donahue from the National Eating Disorder Information Centre tell us how people with eating disorders may be impacted by the constant discussions about weight loss.
Finally, Dr. Stephen Glazer, Medical Director for the Bariatric Surgical Program at Humber River Hospital in Toronto on how weight stigma can be internalized.
You can contact the National Eating Disorders Information Centre at their toll-free helpline at 1-866-NEDIC-20 or visit their website.
Questions? Comments? Ideas? E-mail us at thedecibel@globeandmail.com